In 2021, Idaho had the highest death rate from skin cancer, with an estimated 2.8 people out of 100,000 dying from melanoma. This statistic shows the death rate for melanoma of the skin in the U.S. in 2021, by state, per 100,000 population.

Mortality from malignant melanoma (ICD-10 C43 equivalent to ICD-9 172). To reduce deaths from malignant melanoma. Legacy unique identifier: P00644

In 2022, it was estimated that almost **** thousand people died from melanoma skin cancer in Europe, most of which were recorded in Germany with almost *** thousand cases, while around *** thousand deaths were registered in Italy. This statistic displays the estimated number of melanoma skin cancer deaths in European Union countries in 2022.

As of 2021, non-Hispanic white people in the United States had the highest incidence rates of skin cancer among all races and ethnicities. Skin cancer is one of the most commonly occurring cancers in the world. Furthermore, the United States is among the countries with the highest rates of skin cancer worldwide. Skin cancer in the U.S. There are a few different types of skin cancer and some are more deadly than others. Basal and squamous skin cancers are more common and less dangerous than melanomas. Among U.S. residents, skin cancer has been demonstrated to be more prevalent among men than women. Skin cancer is also more prevalent among older adults. With treatment and early detection, skin cancers have a high survival rate. Fortunately, in recent years the U.S. has seen a reduction in the rate of death from melanoma. Skin cancer prevention Avoiding and protecting exposed skin from the sun (and other sources of UV light) is the primary means of preventing skin cancer. However, a survey of U.S. adults from 2024 found that around ******* never used sunscreen.

In the years 2016 to 2020, over ** percent of patients diagnosed with melanoma of the skin in England aged between 15 and 44 years of age would survive for at least one year, while patients this age had a five-year survival rate of nearly ** percent. The survival rates for melanoma of the skin did generally fall if the patient was older when diagnosed.

Mortality from skin cancers other than malignant melanoma (ICD-10 C44 equivalent to ICD-9 173). To reduce deaths from skin cancers other than malignant melanoma. Legacy unique identifier: P00659

In the period 2013 to 2017, almost 99 percent of those aged between 15 and 44 years who were diagnosed with melanoma skin cancer in England survived for at least one year after being diagnosed, while over 96 percent in this age group survived for five years. Over the period provided, the older age groups have a lower survival rate than the younger age groups.

Years of life lost due to mortality from malignant melanoma (ICD-10 C43). Years of life lost (YLL) is a measure of premature mortality. Its primary purpose is to compare the relative importance of different causes of premature death within a particular population and it can therefore be used by health planners to define priorities for the prevention of such deaths. It can also be used to compare the premature mortality experience of different populations for a particular cause of death. The concept of years of life lost is to estimate the length of time a person would have lived had they not died prematurely. By inherently including the age at which the death occurs, rather than just the fact of its occurrence, the calculation is an attempt to better quantify the burden, or impact, on society from the specified cause of mortality. Legacy unique identifier: P00274

PurposeCutaneous malignant melanoma (CMM) always presents as a complex disease process with poor prognosis. The objective of the present study was to explore the influence of solitary or multiple cancers on the prognosis of patients with CMM to better understand the landscape of CMM.MethodsWe reviewed the records of CMM patients between 2004 and 2015 from the Surveillance, Epidemiology, and End Results Program. The cumulative incidence function was used to represent the probabilities of death. A novel causal inference method was leveraged to explore the risk difference to death between different types of CMM, and nomograms were built based on competing risk models.ResultsThe analysis cohort contained 165,043 patients with CMM as the first primary malignancy. Patients with recurrent CMM and multiple primary tumors had similar overall survival status (p = 0.064), while their demographics and cause-specific death demonstrated different characteristics than those of patients with solitary CMM (p < 0.001), whose mean survival times are 75.4 and 77.3 months and 66.2 months, respectively. Causal inference was further applied to unveil the risk difference of solitary and multiple tumors in subgroups, which was significantly different from the total population (p < 0.05), and vulnerable groups with high risk of death were identified. The established competing risk nomograms had a concordance index >0.6 on predicting the probabilities of death of CMM or other cancers individually across types of CMM.ConclusionPatients with different types of CMM had different prognostic characteristics and different risk of cause-specific death. The results of this study are of great significance in identifying the high risk of cause-specific death, enabling targeted intervention in the early period at both the population and individual levels.

In 2021, around 13,883 people aged 70 to 74 years were diagnosed with melanoma of the skin or another non-epithelial skin cancer, the highest number of any age group. This statistic shows the number of new skin cancer cases in the U.S. in 2021, by age.

This csv reports melanoma registration rates, per 100,000 population, by age. Age is grouped in 5 year segments (eg 0–4 years old, 5–9 years old). New Zealand and Australia have the world’s highest rates of melanoma, the most serious type of skin cancer. Melanoma is mainly caused by exposure to ultraviolet (UV) light, usually from the sun. New Zealand has naturally high UV levels, especially during summer.
The risk of developing melanoma is affected by factors such as skin colour and type, family history, and the amount of sun exposure. Melanoma can affect people at any age, but the chance of developing a melanoma increases with age. We report on age-standardised rates of melanoma to account for the increasing proportion of older people in our population. Our data on melanoma registrations come from the New Zealand Cancer Registry and the Ministry of Health's Mortality Collection. The passing of the Cancer Registry Act 1993 and Cancer Registry Regulations 1994 led to significant improvements in data quality and coverage (Ministry of Health, 2013). A sharp increase in registrations after 1993 is likely to have been related to these legislative and regulatory changes; for this reason we have only analysed data from 1996. 2014–15 data are provisional and subject to change. More information on this dataset and how it relates to our environmental reporting indicators and topics can be found in the attached data quality pdf.

Supplementary Materials: Demographic Characteristics (Table 1) and Skin Cancer Prevalence and Risk Factors with Differing Markers of Acculturation (Table 2)

This dataset presents the footprint of cancer mortality statistics in Australia for all cancers combined and the 6 top cancer groupings (colorectal, leukaemia, lung, lymphoma, melanoma of the skin and pancreas) and their respective ICD-10 codes. The data spans the years 2009-2013 and is aggregated to Greater Capital City Statistical Areas (GCCSA) from the 2011 Australian Statistical Geography Standard (ASGS).

Mortality data refer to the number of deaths due to cancer in a given time period. Cancer deaths data are sourced from the Australian Institute of Health and Welfare (AIHW) 2013 National Mortality Database (NMD).

For further information about this dataset, please visit:

• Australian Institute of Health and Welfare - Cancer Incidence and Mortality Across Regions (CIMAR) books.

• Australian Institute of Health and Welfare - 2013 National Mortality Database.

Please note:

• AURIN has spatially enabled the original data.

• Due to changes in geographic classifications over time, long-term trends are not available.

• Values assigned to "n.p." in the original data have been removed from the data.

• The Australian and jurisdictional totals include people who could not be assigned a GCCSA. The number of people who could not be assigned a GCCSA is less than 1% of the total.

• The Australian total also includes residents of Other Territories (Cocos (Keeling) Islands, Christmas Island and Jervis Bay Territory).

• Cause of Death Unit Record File data are provided to the AIHW by the Registries of Births, Deaths and Marriages and the National Coronial Information System (managed by the Victorian Department of Justice) and include cause of death coded by the Australian Bureau of Statistics (ABS). The data are maintained by the AIHW in the NMD.

• Year refers to year of occurrence of death for years up to and including 2012, and year of registration of death for 2013. Deaths registered in 2011 and earlier are based on the final version of cause of death data; deaths registered in 2012 and 2013 are based on revised and preliminary versions, respectively and are subject to further revision by the ABS.

• Cause of death information are based on underlying cause of death and are classified according to the International Classification of Diseases and Related Health Problems (ICD). Deaths registered in 1997 onwards are classified according to the 10th revision (ICD-10).

• Colorectal deaths presented are underestimates. For further information, refer to "Complexities in the measurement of bowel cancer in Australia" in Causes of Death, Australia (ABS cat. no. 3303.0).

In 2022, Australia had the fourth-highest total number of skin cancer cases worldwide and the highest age-standardized rate, with roughly 37 cases of skin cancer per 100,000 population. The graph illustrates the rate of skin cancer in the countries with the highest skin cancer rates worldwide in 2022.

According to Cognitive Market Research, the Metastatic Melanoma Drug Market Size will be USD XX Billion in 2024 and is set to achieve a market size of USD XX Billion by the end of 2033 growing at a CAGR of XX% from 2025 to 2033.

The North America Metastatic Melanoma market size was USD XX Million in 2021 and it is expected to reach USD XX Million in 2033.
The Europe Metastatic Melanoma market size was USD XX Million in 2021 and it is expected to reach USD XX Million in 2033.
The Asia Pacific Metastatic Melanoma market size was USD XX Million in 2021 and it is expected to reach USD XX Million in 2033.
The South America Metastatic Melanoma market size was USD XX Million in 2021 and it is expected to reach USD XX Million in 2033.
The Middle East and Africa Metastatic Melanoma of market size was USD XX Million in 2021 and it is expected to reach USD XX Million in 2033.

Market Dynamics of

Metastatic Melanoma Drug Market

Key Drivers for

Metastatic Melanoma Drug Market

Global Melanoma Cases Are Increasing: More melanoma cases are being caused by genetic predisposition, increased UV exposure, and altered lifestyles, which is driving up need for efficient medication treatments, particularly in North America, Europe, and Australia. For instance, May 2024, according to the news reported, A UK cancer charity is urging increased sun protection due to rising melanoma rates, with predictions for 20,800 cases this year, a record high. This rise is attributed to factors like an aging population and growing awareness, with almost 17,000 melanoma cases potentially preventable annually through sun safety measures. Researchers highlight that the increase is widespread, affecting all age groups, but particularly pronounced in older adults, especially those over 80. The increasing incidence of melanoma, particularly in older adults, is driving the growth of the metastatic melanoma drug market.

Developments in Targeted Drugs and Immunotherapy: The metastatic melanoma therapeutics market is experiencing important growth due to the rising adoption of targeted and immunotherapies. This trend is driven by the increasing availability of these therapies, their effectiveness in improving patient outcomes, and the growing number of melanoma cases worldwide. Immunotherapies, in particular, have revolutionized the treatment landscape for metastatic melanoma, offering new hope for patients and extending survival rates. The market is also fueled by the development of new drugs and combination therapies, both targeted and immunotherapy-based. These advancements, coupled with increased awareness and the need for better treatment options for a growing patient population, are expected to continue driving market expansion. Expanding R&D Projects and Clinical Trials: The metastatic melanoma drug market is experiencing considerable growth fueled by robust research and development (R&D) and growing innovation. This is driven by a rising need for effective treatments as metastatic melanoma prevalence increases, and advanced therapies like immunotherapies and targeted therapies emerge. The market anticipates continued expansion due to the availability of new pipeline drugs and the increasing adoption of these advanced therapies. For instance, March 2025, a new combination drug therapy, involving oral medications defactinib and avutometinib, shows promise in treating melanoma brain metastasis, which is a significant cause of death in melanoma patients. The research, led by Sheri Holmen at Huntsman Cancer Institute, aims to address the unmet need for effective treatments when melanoma spreads to the brain. This combination therapy aims to make treatment more accessible for melanoma patients who have difficulty traveling long distances and thus the rises the opportunity in the market of Metastatic Melanoma Drug. https://www.htworld.co.uk/news/research-news/new-drug-therapy-combination-shows-promise-for-advanced-melanoma-patients-ddev25/ Innovation continues to be a key driver in the metastatic melanoma therapeutics market, with companies utilizing advanced technologies to develop new treatments. Collaborations between leading companies are also shaping the market landscape, concentrating on enhancing treatment efficacy and trying new therapeutic modalities.

Key Restraints for

Metastatic Melanoma Drug Market

High Treatme...

This study aims to provide a comprehensive overview of sex-related characteristics of cutaneous malignant melanoma (CMM), with special reference to its incidence, clinicopathological profile, overall survival, and treatment-related costs. This retrospective cohort study included all 1,279 CMM patients who were registered in 2015 in the Veneto Cancer Registry (a population-based registry including all 4,900,000 regional residents). The by-sex comparisons included tumor stage and site, histological subtype, and other clinical-pathological variables. A Cox regression analysis was used to test the association between sex and survival, adjusting for the main covariates. Treatment costs were calculated by linking patients with several administrative regional databases. Age-specific incidence rates were significantly higher for men among people >50 years old. For men, the trunk was the most common primary site (59.3%), whereas for women the lower limbs (32.1%) were the most common primary site, followed by the trunk (31.8%), which was lower than for men (p < 0.001). At presentation, the frequency of early stage CMM was higher among women, who also featured a significantly lower risk of death (p = 0.016), after adjusting for covariates. Men also incurred higher costs for melanoma treatment in the first year after their diagnosis. Among younger adults, CMM was more common in women, whereas among older adults, it was more common in men. Sex also influences patients' histopathological characteristics at diagnosis. Women had better overall survival after adjusting for demographic, pathological, and clinical profiles. The costs of treatment were also lower for women with CMM.

In the period from 2014 to 2020, the probability of a person in the U.S. surviving the first five years after being diagnosed with melanoma of the skin when it was confined locally was ** percent. This statistic shows the ********* relative survival rate for melanoma skin cancer in the U.S. from 2014 to 2020, by stage at diagnosis.

This data was taken from the R `lattice' package. The data is described in the package as follows: These data from the Connecticut Tumor Registry present age-adjusted numbers of melanoma skin-cancer incidences per 100,000 people in Connecticut for the years from 1936 to 1972. Format: A csv file has 37 observations on the following 2 variables. year: years 1936 to 1972. incidence: rate of melanoma cancer per 100,000 population.

New Zealand and Australia have the world’s highest rates of melanoma, the most serious type of skin cancer. Melanoma is mainly caused by exposure to ultraviolet (UV) light, usually from the sun. New Zealand has naturally high UV levels, especially during summer.
The risk of developing melanoma is affected by factors such as skin colour and type, family history, and the amount of sun exposure. Melanoma can affect people at any age, but the chance of developing a melanoma increases with age. We report on age-standardised rates of melanoma to account for the increasing proportion of older people in our population. Our data on melanoma registrations come from the New Zealand Cancer Registry and the Ministry of Health's Mortality Collection. The passing of the Cancer Registry Act 1993 and Cancer Registry Regulations 1994 led to significant improvements in data quality and coverage (Ministry of Health, 2013). A sharp increase in registrations after 1993 is likely to have been related to these legislative and regulatory changes; for this reason we have only analysed data from 1996. Trend direction was assessed using the Theil-Sen estimator and the Two One-Sided Test (TOST) for equivalence at the 95% confidence level. More information on this dataset and how it relates to our environmental reporting indicators and topics can be found in the attached data quality pdf.

Mobile Applications for Melanoma Detection Market Outlook

In 2023, the global market size for mobile applications dedicated to melanoma detection was valued at approximately USD 250 million. With increasing awareness and technological advancements, this market is expected to grow at an impressive compound annual growth rate (CAGR) of 18.5% from 2024 to 2032, reaching an anticipated USD 950 million by the end of the forecast period. The burgeoning need for early detection and personalized healthcare solutions are the primary growth factors driving this market. As the incidence of skin cancer continues to rise, the market for mobile applications that facilitate early and accurate melanoma detection is set to expand significantly.

One of the key growth factors in the expansion of mobile applications for melanoma detection is the increasing prevalence of skin cancer worldwide. Melanoma, being one of the most aggressive forms of skin cancer, necessitates early detection to improve patient prognosis and survival rates. The World Health Organization has reported a rising trend in skin cancer cases, which has heightened the demand for effective diagnostic tools. Mobile applications offer a non-invasive, accessible, and cost-effective solution for preliminary melanoma screening, which has been a significant driver of their adoption across diverse demographics and geographies. Furthermore, the pressing demand for remote healthcare solutions, exacerbated by the COVID-19 pandemic, has accelerated the adoption of health-related mobile applications, including those focused on melanoma detection.

Technological advancements in artificial intelligence (AI) and machine learning (ML) are also propelling the market's growth. AI-powered mobile applications can analyze skin lesions with remarkable accuracy, offering immediate feedback and recommendations for further medical consultation if necessary. These applications often employ deep learning algorithms trained on vast datasets of skin images to identify and classify potential melanoma cases. With continuous improvements in AI and ML technologies, the precision and reliability of these applications are set to enhance, thereby strengthening their credibility among healthcare professionals and end-users. The integration of such advanced technologies has made these applications a viable tool for preliminary diagnosis, fostering their market penetration.

Another significant growth factor is the increasing emphasis on preventive healthcare among consumers. There is a growing awareness among the general public about the risks associated with skin cancer and the importance of early detection. This has led to a proactive approach towards health monitoring, where individuals are more inclined to utilize digital tools for self-diagnosis and routine health checks. Mobile applications for melanoma detection not only cater to this need but also empower individuals by providing them with the knowledge and resources to monitor their skin health regularly. This shift in consumer behavior towards preventive care is expected to sustain the market's growth momentum throughout the forecast period.

Acral Lentiginous Melanoma, though less common than other types, is a particularly aggressive form of melanoma that often appears on the palms, soles, or under the nails. Its subtle presentation can lead to delayed diagnosis, making early detection crucial. Mobile applications designed for melanoma detection can play a pivotal role in identifying such atypical presentations by providing users with tools to monitor changes in these specific areas. The ability to capture and analyze images of suspicious lesions on hard-to-reach areas using AI-driven technology enhances the likelihood of early intervention. As awareness of acral lentiginous melanoma grows, the demand for specialized diagnostic tools within mobile applications is expected to increase, further driving market growth.

Regionally, North America leads the market, driven by the high prevalence of skin cancer, robust healthcare infrastructure, and significant technology adoption. The region's market dominance is further supported by favorable government initiatives promoting digital health solutions. Additionally, Europe showcases a strong growth trajectory due to increasing healthcare expenditure and rising awareness about skin cancer. Meanwhile, the Asia Pacific region is poised for substantial growth, reflecting an increasing incidence rate of melanoma, coupled with rapid technological advancements and growing smartphone penetration. The market i